Study medicine for BRAF-mutated advanced solid tumors
Part of Brain & nervous system, Cancer, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor (tumors like lung, breast, etc.), not colorectal cancer
- Your scans show measurable signs of cancer that can be followed (per RECIST 1.1)
- Your tumor has the BRAF V600 mutation
- You have had prior treatment for your specific tumor type (as required for your cohort)
- Your blood and organ tests meet the trial’s safety requirements
- Your cancer is the focus of this trial (you don’t have another active cancer within the last 3 years)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
This Phase 1 trial studies whether targeted medicines (dabrafenib and trametinib) plus radiation can control an aggressive thyroid cancer with a specific BRAF gene change. It may help by attacking cancer cells that have this mutation and using focused radiation to improve tumor control.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.